Search Results
Jun 01, 2026, 08:36 ET SoLo Funds Launches for Enterprises with SoLo NowCAST™, A Real-Time Predictive Analytics Tool for U.S. Inflation
geographies. Rather than relying on surveys or limited credit card data, the CVI captures a broader picture of consumer financial activity — how people prepare to spend, repay, and borrow, not just what they've already purchased.The CVI is designed to complement existing models by offering a forward-looking
More news about: SoLo Funds
May 18, 2026, 07:00 ET Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System
ACIST's automated contrast delivery technology, ACIST CVi®, which revolutionized cardiac catheterization laboratory contrast management by replacing manual injection with automated, real-time precision. Clinical use of the ACIST CVi® system has demonstrated outcomes compared to manual
More news about: Bracco Group
May 06, 2026, 09:10 ET AIROS Medical Introduces ARTAIRA Travel Case to Support Therapy Continuity for PAD Patients
The AIROS 6P and AIROS 8P compression devices treat lower extremity, upper extremity, and truncal lymphedema as well as chronic venous insufficiency (CVI). The ARTAIRA® arterial compression device treats intermittent claudication, rest pain, diabetic foot and arterial ulcers, and ischemia. The
More news about: AIROS Medical
May 06, 2026, 08:00 ET Icahn Enterprises L.P. (Nasdaq: IEP) Today Announced Its First Quarter 2026 Financial Results
of our long position in CVI, offset in part by losses on refining hedges in the Investment segment of $320 million, the Holding Company's net interest expense of $79 million and IEP distribution payable of $51 million. Excluding refining hedges and $605 million of gains in CVI, the Investment segment
More news about: Icahn Enterprises L.P.
Apr 09, 2026, 08:05 ET CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
https://iscc-system.org/about/who-we-are.]CVI data on file, 2023.CVI data on file, 2021-2025.CVI data on file, 2024-2025.CVI data on file as of 03/2026.Plastic Bank, CVI data on file, 2025SA17810/APP163993About CooperVisionCooperVision,
More news about: CooperVision, Inc.
Mar 31, 2026, 10:15 ET AIROS Medical Appoints Dr. John Evans as Lead Medical Advisor
The AIROS 6P and AIROS 8P compression devices treat lower extremity, upper extremity, and truncal lymphedema as well as chronic venous insufficiency (CVI). The ARTAIRA® arterial compression device treats intermittent claudication, rest pain, diabetic foot and arterial ulcers, and ischemia. The company's
More news about: AIROS Medical
Mar 26, 2026, 18:16 ET VERIGRAFT 將其首個有望根治慢性靜脈功能不全的療法，推進至關鍵的第 II/III 期臨床試驗
此里程碑的達成，正值再生醫學及個人化生物製劑在全球投資者及醫療體系中備受矚目之際。VERIGRAFT 的全生物性方法使用個人化組織，那就不必進行免疫抑制治療，為 CVI 的根治療法開闢了新路徑。 整個製造過程可在 10 天內完成，讓 VERIGRAFT 的療法既能規模化生產，也可臨床應用。 此項第 II/III 期研究的試驗地點設於西班牙、荷蘭及波蘭。作為先進治療醫療產品 (ATMP)，VERIGRAFT 的臨床開發計劃設計用於在有限的患者群體中，獲取強而有力的臨床數據。 公司力求在 2028 年獲取歐美市場的上市許可。慢性靜脈功能不全 (CVI) 是一種常被忽視的病情惡化血管疾病，患者腿部靜脈無法有效地將血液輸送回心臟，導致腿部靜脈壓力持續偏高。
More news about: VERIGRAFT
Mar 26, 2026, 00:18 ET 베리그래프트, 만성 정맥 부전 최초의 잠재적 완치 치료제를 핵심 2/3상 임상시험으로 진전
중기존 완치 치료법이 없는 수백만 명의 환자군을 대상으로 하는 '진정으로 혁신적인' 재생 의학완전 생물학적 이식으로 면역억제제 필요성 제거 및 자연적 기능 회복92개 등록 특허로 보호되는 확장 가능한 공정CVI 시장, 2034년까지 미화 59억 5100만 달러 규모로 성장 전망*기존 투자자들로부터 미화 1000만 달러 자금 조달 지원예테보리, 스웨덴, 2026년
More news about: VERIGRAFT
Mar 25, 2026, 08:00 ET VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
Insufficiency (CVI) is a progressive and under-recognized vascular disease in which the veins in the legs fail to efficiently return blood to the heart, leading to sustained elevated venous pressure in the leg veins. Driven by factors such as ageing, obesity, and sedentary lifestyles, CVI represents a
More news about: VERIGRAFT
Mar 10, 2026, 10:08 ET Cv International, Introduces Nitro-Lite™ to their WindSuite, A Turn‑Key Nitrogen Servicing Platform for Wind Turbines
solution that improves safety, increases uptime, and pays for itself quickly."Metko noted that Cv International also offers financing through Cvi Capital, allowing operators to deploy WindSuite with minimal upfront investment.WindSuite™ Product highlightsNitro-Lite:
More news about: Cv International
Feb 25, 2026, 08:00 ET Icahn Enterprises L.P. (Nasdaq: IEP) Today Announced Its Fourth Quarter and Full Year 2025 Financial Results
decrease of $654 million compared to September 30, 2025. The decrease was primarily due to a decrease of $778 million of our long position in CVI and the Holding Company's net interest expense of $75 million. The decrease was offset in part by the positive performance from the Funds of $261 millionFinancial
More news about: Icahn Enterprises L.P.
Feb 12, 2026, 02:00 ET Bracco and ACIST Medical Systems Announce European Launch of ACIST Pro™ Diagnostic System
ACIST's automated contrast delivery technology, ACIST CVi®, which revolutionized cardiac catheterization laboratory contrast management by replacing manual injection with automated, real-time precision. Clinical use of the ACIST CVi® system has demonstrated outcomes compared to manual
More news about: Bracco Group
Feb 12, 2026, 02:00 ET Bracco and ACIST Medical Systems Announce European Launch of ACIST Pro™ Diagnostic System
ACIST's automated contrast delivery technology, ACIST CVi®, which revolutionized cardiac catheterization laboratory contrast management by replacing manual injection with automated, real-time precision. Clinical use of the ACIST CVi® system has demonstrated outcomes compared to manual
More news about: Bracco Group
Feb 10, 2026, 07:00 ET CooperVision Launches MiSight® 1 day in Japan; Becomes First Myopia Control Contact Lens in Leading Vision Care Market
among school children in Japan. JAMA Ophthalmol. 2019; 137(11): 1233-9.2 Contact Lens Institute data, Q3 2025.3 CVI data on file, 2025.4 Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents
More news about: CooperVision, Inc.
Feb 04, 2026, 09:28 ET AIROS Medical Launches ARTAIRA Compression Device to Treat Patients with Symptoms of Peripheral Arterial Disease (PAD)
The AIROS 6P and AIROS 8P compression devices treat lower extremity, upper extremity, and truncal lymphedema as well as chronic venous insufficiency (CVI). The ARTAIRA® arterial compression device treats intermittent claudication, rest pain, diabetic foot and arterial ulcers, and ischemia. The company's
More news about: AIROS Medical
Jan 14, 2026, 10:27 ET AIROS Medical Announces Five-Year Warranty on Lymphedema Pneumatic Compression Devices
garments that treat lymphedema present in the upper extremities, lower extremities, and truncal region. Patients battling chronic venous insufficiency (CVI) can also utilize prescription-only devices and garments manufactured by AIROS. Visit
More news about: AIROS Medical
Jan 07, 2026, 12:36 ET Spoločnosť CooperVision uvádza na trh mäkké kontaktné jednodňové šošovky MyDay® MiSight® 1 day na kontrolu krátkozrakosti
https://www.aop.org.uk/advice-and-support/clinical/vision-standardsÚdaje CVI v súbore z roku 2025. Interné odhady modelovania nositeľov na celom svete za 12-mesačné obdobie od októbra 2024 do septembra 2025Chamberlain P. a kol. 3-ročná randomizovaná klinická štúdia šošoviek MiSight® na kontrolu krátkozrakosti. OVS 2019; 96(8):556-567. -Údaje CVI v súbore,
More news about: CooperVision, Inc.
Jan 07, 2026, 11:56 ET CooperVision wprowadza na rynek jednodniowe miękkie soczewki kontaktowe MyDay® MiSight® 1 day do kontroli krótkowzroczności
własne CVI, 2025 r. Prospective, 1-week, double masked, bilateral study with MiSight 1 day silicone hydrogel (Prospektywne tygodniowe obustronne badanie metodą podwójnie ślepej próby z użyciem soczewek silikonowo-hydrożelowych MiSight 1 day). N=32 osoby w wieku 8-18 lat.-Dane własne CVI, 2025
More news about: CooperVision, Inc.
Jan 06, 2026, 12:15 ET CooperVision bringt weiche MyDay® MiSight® 1 day Kontaktlinsen zur Myopie-Kontrolle auf den Markt
https://www.aop.org.uk/advice-and-support/clinical/vision-standardsCVI-Daten in der Datei, 2025. Interne Schätzungen der globalen Trägermodelle für den 12-Monats-Zeitraum von Oktober 2024 bis September 2025Chamberlain P, et al. Eine randomisierte klinische 3-Jahres-Studie mit MiSight®-Linsen zur Myopiekontrolle. OVS 2019; 96(8):556-567. –CVI-Daten
More news about: CooperVision, Inc.
Jan 06, 2026, 10:56 ET Společnost CooperVision uvede na trh měkké kontaktní čočky MyDay® MiSight® 1 day pro kontrolu krátkozrakosti
https://www.aop.org.uk/advice-and-support/clinical/vision-standardsÚdaje CVI v archivu 2025. Interní globální modelované odhady u nositelů za dvanáctiměsíční období od října 2024 do září 2025Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567. -Údaje CVI v archivu, 2025.
More news about: CooperVision, Inc.
Jan 06, 2026, 08:28 ET CooperVision lanzará las lentes de contacto blandas MyDay® MiSight® de 1 día para el control de la miopía
https://www.aop.org.uk/advice-and-support/clinical/vision-standardsCVI data on file 2025. Internal global wearer modeling estimates for the 12-month period of October 2024 to September 2025Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567. -CVI data on file, 2025.
More news about: CooperVision, Inc.
Jan 06, 2026, 08:00 ET CooperVision to Launch MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses
https://www.aop.org.uk/advice-and-support/clinical/vision-standardsCVI data on file 2025. Internal global wearer modeling estimates for the 12-month period of October 2024 to September 2025Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567. -CVI data on file, 2025.
More news about: CooperVision, Inc.
Dec 16, 2025, 09:00 ET Aidoc Deepens Clinical AI Leadership Through Strategic Partnerships in Neurosciences
Collaborations with Cercare Medical and Circle CVI bring advanced AI for MR Perfusion and automated ASPECTS scoring to Aidoc's aiOS™ platformNEW YORK, Dec. 16, 2025 /PRNewswire/ -- Aidoc, the leading
More news about: Aidoc
Nov 17, 2025, 11:23 ET United Vein & Vascular Centers Expands Atlanta Access with Opening of Inman Park Clinic
chronic venous insufficiency (CVI). RFA helps relieve symptoms such as leg pain, heaviness, swelling, and fatigue caused by poor circulation.
More news about: United Vein & Vascular Centers
Nov 13, 2025, 10:48 ET Cv International Unveils Maintainer Series TailStand™ and StarBridge™
footprints. Modular utility suite: Integrated DimpleDeck™ anti‑slip surfaces, lockable casters, Cvi jacks for accurate leveling, modular tool and hardware trays, powered workstations, lighting, compressed air, and data connectivity for test equipment
More news about: Cv International